ClinicalTrials.gg
CompletedNCT01946412Updated Feb 1, 2017Results posted

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

A Phase 3 interventional study of Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 16 sites in 3 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2017-02-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
64th of 84
33 · median 70
Started
2013
with 7 others
Phase 3
45 of 84
none open now
Registered
27th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 64th largest by enrollment, is one of 8 that started in 2013, is one of 45 in phase 3, and was the 27th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to provide information regarding the long-term safety and pharmacodynamics of ivacaftor treatment in the pediatric population younger than 6 years of age with Cystic Fibrosis (CF) who have a CFTR gating mutation in at least 1 allele and will further explore the efficacy of long-term ivacaftor treatment in this population of patients with CF.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Cystic Fibrosis
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Ivacaftor Arm):

  1. Completed the last study visit of the treatment period of the previous study (NCT01705145)
  2. Hematology, serum chemistry, and vital signs results on Day 1 with no abnormalities that would interfere with the study assessments, as judged by the investigator
  3. As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions and the parent or legal guardian should be able to ensure that the subject assents to participation in the study to the degree the subject can assent, and that the subject will comply with and is likely to complete the study as planned

Inclusion Criteria (Observational Arm):

  1. Subjects who completed their assigned study drug treatment in the previous study (NCT01705145) and elected not to enroll in the ivacaftor arm and subjects who prematurely discontinued treatment in the previous study and received at least 1 dose of study drug treatment in the previous study will be eligible for enrollment in the observational arm.

Exclusion Criteria (Ivacaftor Arm):

  1. Subjects who prematurely discontinued from the previous study
  2. History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject
  3. Subjects with a history of study treatment intolerance as observed in their previous study that, in the opinion of the investigator, might pose an additional risk in administering study drug to the subject
  4. Subjects receiving commercially-available ivacaftor treatment
  5. Subject was unable to complete an adequate slit-lamp examination at the last ophthalmologic examination in the previous study

Exclusion Criteria: (Observational Arm)

  1. Subjects receiving ivacaftor treatment will not be eligible for enrollment in the observational arm.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • No intervention
    Observational Arm
  • Experimental
    Ivacaftor

    Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be: * 50 mg q12h for subjects 2 to \<6 years of age and \<14 kg, * 75 mg q12h for subjects 2 to \<6 years of age and ≥ 14 kg, or * 150 mg q12h for subjects ≥ 6 years of age.

    Drug: Ivacaftor

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation was considered treatment-emergent.

    Time frame: Day 1 up to Week 97 (for participants who completed study drug dosing); Day 1 up to 24 weeks after the last dose (up to Week 108, for participants who prematurely discontinued study drug dosing)

Secondary outcomes

  1. Absolute Change From Baseline of Parent Study in Sweat Chloride at Week 24, 48, 72 and 84

    Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).

    Time frame: Baseline (study 108), Week 24, 48, 72 and 84 (study 109)

  2. Absolute Change From Baseline of Study 109 in Sweat Chloride at Week 24, 48, 72 and 84

    Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of \>=15 microliter was required for determination of sweat chloride. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).

    Time frame: Baseline (study 109), Week 24, 48, 72 and 84 (study 109)

  3. Absolute Change From Baseline of Parent Study in Weight at Week 12, 24, 36, 48, 60, 72 and 84

    Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145)

    Time frame: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

  4. Absolute Change From Baseline of Study 109 in Weight at Week 12, 24, 36, 48, 60, 72 and 84

    Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).

    Time frame: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

  5. Absolute Change From Baseline of Parent Study in Stature at Week 12, 24, 36, 48, 60, 72 and 84

    Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).

    Time frame: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

  6. Absolute Change From Baseline of Study 109 in Stature at Week 12, 24, 36, 48, 60, 72 and 84

    Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).

    Time frame: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

  7. Absolute Change From Baseline of Parent Study in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84

    BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).

    Time frame: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

  8. Absolute Change From Baseline of Study 109 in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84

    BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).

    Time frame: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

07

Results

Posted Feb 1, 2017

Participant flow

This was a Phase 3, multicenter, 2 arm study in participants who received at least 1 dose of study drug in parent study VX11-770-108 (study 108) (NCT01705145).

Participant flow — Overall Study
MilestoneIvacaftor
Started33
Completed28
Not completed5
Withdrew: Adverse event1
Withdrew: Non-compliance1
Withdrew: Continued with commercial kalydeco2
Withdrew: Difficulty in swallowing1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation was considered treatment-emergent.

Time frame:
Day 1 up to Week 97 (for participants who completed study drug dosing); Day 1 up to 24 weeks after the last dose (up to Week 108, for participants who prematurely discontinued study drug dosing)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsIvacaftor 50 mgIvacaftor 75 mg
AEs924
SAEs65
SecondaryAbsolute Change From Baseline of Parent Study in Sweat Chloride at Week 24, 48, 72 and 84

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).

Time frame:
Baseline (study 108), Week 24, 48, 72 and 84 (study 109)
Reported as:
Mean · millimole per liter (mmol/L)
Absolute Change From Baseline of Parent Study in Sweat Chloride at Week 24, 48, 72 and 84
millimole per liter (mmol/L)Ivacaftor 50 mgIvacaftor 75 mg
Baseline (n=7,22)93.1 ± 16.299.6 ± 13.6
Absolute Change at Week 24 (n=6,18)-62.1 ± 12.4-48.5 ± 18.4
Absolute Change at Week 48 (n=6,15)-29.3 ± 37.8-51.8 ± 27.1
Absolute Change at Week 72 (n=7,14)-46.4 ± 16.0-52.9 ± 26.7
Absolute Change at Week 84 (n=6,14)-46.5 ± 31.0-58.1 ± 23.9
SecondaryAbsolute Change From Baseline of Study 109 in Sweat Chloride at Week 24, 48, 72 and 84

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of \>=15 microliter was required for determination of sweat chloride. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).

Time frame:
Baseline (study 109), Week 24, 48, 72 and 84 (study 109)
Reported as:
Mean · mmol/L
Absolute Change From Baseline of Study 109 in Sweat Chloride at Week 24, 48, 72 and 84
mmol/LIvacaftor 50 mgIvacaftor 75 mg
Baseline (n= 8,23)47.8 ± 23.352.9 ± 23.1
Absolute Change at Week 24 (n=7,18)-4.3 ± 31.63.4 ± 15.9
Absolute Change at Week 48 (n=7,17)18.1 ± 39.5-4.5 ± 22.6
Absolute Change at Week 72 (n=8,15)-1.5 ± 24.3-6.0 ± 20.8
Absolute Change at Week 84 (n=7,16)-2.4 ± 44.2-11.2 ± 25.4
SecondaryAbsolute Change From Baseline of Parent Study in Weight at Week 12, 24, 36, 48, 60, 72 and 84

Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145)

Time frame:
Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Reported as:
Mean · kilogram (kg)
Absolute Change From Baseline of Parent Study in Weight at Week 12, 24, 36, 48, 60, 72 and 84
kilogram (kg)Ivacaftor 50 mgIvacaftor 75 mg
Baseline (n=9, 24)12.5 ± 1.116.8 ± 1.8
Absolute Change at Week 12 (n= 9, 23)1.3 ± 0.41.9 ± 0.7
Absolute Change at Week 24 (n=9, 23)2.0 ± 0.62.5 ± 0.9
Absolute Change at Week 36 (n=9, 23)2.4 ± 0.73.1 ± 1.0
Absolute Change at Week 48 (n=9, 22)2.6 ± 0.93.4 ± 1.1
Absolute Change at Week 60 (n=9, 22)3.2 ± 1.04.0 ± 1.3
Absolute Change at Week 72 (n=9, 20)3.4 ± 0.94.8 ± 1.6
Absolute Change at Week 84 (n=9, 19)4.0 ± 1.25.7 ± 1.9
SecondaryAbsolute Change From Baseline of Study 109 in Weight at Week 12, 24, 36, 48, 60, 72 and 84

Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).

Time frame:
Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Reported as:
Mean · Kg
Absolute Change From Baseline of Study 109 in Weight at Week 12, 24, 36, 48, 60, 72 and 84
KgIvacaftor 50 mgIvacaftor 75 mg
Baseline (n= 9, 24)13.5 ± 1.018.3 ± 2.0
Absolute Change at Week 12 (n=9, 23)0.3 ± 0.40.4 ± 0.5
Absolute Change at Week 24 (n=9, 23)1.0 ± 0.51.0 ± 0.7
Absolute Change at Week 36 (n=9, 23)1.4 ± 0.61.6 ± 0.8
Absolute Change at Week 48 (n=9, 22)1.6 ± 0.71.9 ± 0.8
Absolute Change at Week 60 (n=9, 22)2.2 ± 0.82.5 ± 1.1
Absolute Change at Week 72 (n=9, 20)2.4 ± 0.73.3 ± 1.4
Absolute Change at Week 84 (n=9, 19)3.0 ± 1.04.2 ± 1.7
SecondaryAbsolute Change From Baseline of Parent Study in Stature at Week 12, 24, 36, 48, 60, 72 and 84

Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).

Time frame:
Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Reported as:
Mean · Centimeters (cm)
Absolute Change From Baseline of Parent Study in Stature at Week 12, 24, 36, 48, 60, 72 and 84
Centimeters (cm)Ivacaftor 50 mgIvacaftor 75 mg
Baseline (n=9, 24)89.1 ± 4.3102.3 ± 6.4
Absolute Change in Week 12 (n=9, 23)4.6 ± 1.25.4 ± 1.1
Absolute Change in Week 24 (n=9, 23)6.0 ± 1.77.7 ± 3.3
Absolute Change in Week 36 (n=9, 23)7.8 ± 1.88.8 ± 1.4
Absolute Change in Week 48 (n=9, 21)9.7 ± 2.010.4 ± 1.7
Absolute Change in Week 60 (n=9, 22)11.0 ± 2.211.6 ± 2.0
Absolute Change in Week 72 (n=9, 20)12.5 ± 2.613.4 ± 2.0
Absolute Change in Week 84 (n=9, 19)13.6 ± 2.315.0 ± 2.3
SecondaryAbsolute Change From Baseline of Study 109 in Stature at Week 12, 24, 36, 48, 60, 72 and 84

Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).

Time frame:
Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Reported as:
Mean · cm
Absolute Change From Baseline of Study 109 in Stature at Week 12, 24, 36, 48, 60, 72 and 84
cmIvacaftor 50 mgIvacaftor 75 mg
Baseline (n=9, 24)91.7 ± 4.3105.8 ± 6.6
Absolute Change at Week 12 (n=9, 23)2.0 ± 1.11.8 ± 0.9
Absolute Change at Week 24 (n=9, 23)3.4 ± 1.24.1 ± 3.2
Absolute Change at Week 36 (n=9, 23)5.2 ± 1.55.2 ± 1.1
Absolute Change at Week 48 (n=9, 21)7.2 ± 1.36.8 ± 1.3
Absolute Change at Week 60 (n=9, 22)8.4 ± 1.48.0 ± 1.5
Absolute Change at Week 72 (n=9, 20)10.0 ± 2.19.8 ± 1.6
Absolute Change at Week 84 (n=9, 19)11.1 ± 1.711.4 ± 1.9
SecondaryAbsolute Change From Baseline of Parent Study in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84

BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).

Time frame:
Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Reported as:
Mean · Kilogram per square meter (kg/m^2)
Absolute Change From Baseline of Parent Study in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84
Kilogram per square meter (kg/m^2)Ivacaftor 50 mgIvacaftor 75 mg
Baseline (n=9, 24)15.74 ± 0.6916.06 ± 1.15
Absolute Change at Week 12 (n=9, 23)0.03 ± 0.400.09 ± 0.60
Absolute Change at Week 24 (n=9, 23)0.31 ± 0.57-0.12 ± 0.90
Absolute Change at Week 36 (n=9, 23)0.15 ± 0.520.09 ± 0.73
Absolute Change at Week 48 (n=9, 22)-0.31 ± 0.60-0.13 ± 0.77
Absolute Change at Week 60 (n=9, 22)-0.12 ± 0.70-0.06 ± 0.90
Absolute Change at Week 72 (n=9, 20)-0.38 ± 0.680.09 ± 0.97
Absolute Change at Week 84 (n=9, 19)-0.16 ± 0.960.28 ± 0.97
SecondaryAbsolute Change From Baseline of Study 109 in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84

BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).

Time frame:
Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Reported as:
Mean · kg/m^2
Absolute Change From Baseline of Study 109 in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84
kg/m^2Ivacaftor 50 mgIvacaftor 75 mg
Baseline (n= 9, 24)16.07 ± 0.5516.33 ± 1.12
Absolute Change at Week 12 (n= 9, 23)-0.30 ± 0.60-0.16 ± 0.48
Absolute Change at Week 24 (n= 9, 23)-0.02 ± 0.70-0.36 ± 1.03
Absolute Change at Week 36 (n= 9, 23)-0.18 ± 0.83-0.16 ± 0.63
Absolute Change at Week 48 (n= 9, 22)-0.64 ± 0.81-0.35 ± 0.57
Absolute Change at Week 60 (n= 9, 22)-0.45 ± 0.82-0.29 ± 0.72
Absolute Change at Week 72 (n= 9, 20)-0.71 ± 0.90-0.21 ± 0.78
Absolute Change at Week 84 (n= 9, 19)-0.49 ± 1.09-0.01 ± 0.87

Adverse events

Collected over Day 1 up to Week 97 (for participants who completed study drug dosing); Day 1 up to 24 weeks after the last dose (up to Week 108, for participants who prematurely discontinued study drug dosing). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ivacaftor 50 mg—6/9 (66.7%)9/9 (100%)
Ivacaftor 75 mg—5/24 (20.8%)24/24 (100%)
Most frequent serious events
Most frequent serious events
EventIvacaftor 50 mgIvacaftor 75 mg
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations3/93/24
Alanine aminotransferase increasedInvestigations2/90/24
Aspartate aminotransferase increasedInvestigations2/90/24
PyrexiaGeneral disorders2/90/24
Respiratory syncytial virus infectionInfections and infestations1/90/24
Adenovirus test positiveInvestigations1/90/24
DehydrationMetabolism and nutrition disorders1/90/24
Enterovirus infectionInfections and infestations0/91/24
Staphylococcal infectionInfections and infestations0/91/24
Seizure anoxicNervous system disorders0/91/24
Most frequent other events
Showing 10 of 100
Most frequent other events
EventIvacaftor 50 mgIvacaftor 75 mg
CoughRespiratory, thoracic and mediastinal disorders8/916/24
PyrexiaGeneral disorders7/96/24
VomitingGastrointestinal disorders6/97/24
Nasal congestionRespiratory, thoracic and mediastinal disorders4/93/24
RhinorrhoeaRespiratory, thoracic and mediastinal disorders4/92/24
RashSkin and subcutaneous tissue disorders3/91/24
Otitis mediaInfections and infestations2/94/24
SinusitisInfections and infestations2/93/24
RhinitisInfections and infestations2/91/24
ConjunctivitisEye disorders2/90/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ivacaftor
Mean3.7 ± 1.04
Gender
Gender(Participants)Ivacaftor
Female6
Male27
08

Study locations

16 sites
  • Birmingham, Alabama, United States
  • Denver, Colorado, United States
  • Atlanta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Boston, Massachusetts, United States
  • Grand Rapids, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Kansas city, Missouri, United States
  • Omaha, Nebraska, United States
  • Salt Lake City, Utah, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Vancouver, British Columbia, Canada
  • Edinburgh, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros. 2019 Nov;18(6):838-843. doi: 10.1016/j.jcf.2019.03.009. Epub 2019 Apr 30. PubMed 31053538 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2013
First posted
Sep 19, 2013
Start
Dec 2013
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Feb 1, 2017
Last update
Feb 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01946412
Collaborators
Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Sep 19, 2013
Start date
Dec 2013
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Feb 1, 2017
Last update
Feb 1, 2017

Study contacts

Adebayo Lawal, M.D.
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion